3 Hotel Owner and Operator, Explosives and Defence Products Maker and Specialty Pharma Company Stocks With a Strong Future Roadmap: SAMHI Hotels, Solar Industries India and Natco Pharma
- November 6, 2026
- Posted by: Neeraj Pandey
- Category: Best Stocks
SAMHI Hotels, Solar Industries India and Natco Pharma: ROE of 15.4% to 26.7% and FY22 to FY26 revenue CAGR of 21.0% to 40.0%. Prices as of 5 Nov 2026.
Quick Answer
The three hotel, explosives and oncology pharma stocks to watch are SAMHI Hotels, Solar Industries India and Natco Pharma. Their return on equity ranges from 15.4% to 26.7%, and their revenue compound annual growth from FY22 to FY26 ranges from 21.0% to 40.0%. Solar Industries India has the highest return on equity at 26.7%, while SAMHI Hotels has the fastest revenue growth at 40.0% a year. Prices are based on the 5 November 2026 close, and this article is educational, not investment advice.
Hotel, explosives and oncology pharma stocks give investors a way to track businesses that sit close to everyday demand in India. SAMHI Hotels, Solar Industries India and Natco Pharma cover a hotel owner and operator, an explosives and defence products maker and a specialty pharma company.
This list covers three hotel, explosives and oncology pharma stocks with complete current figures: SAMHI Hotels, Solar Industries India and Natco Pharma. Every figure comes from the latest reported financials and the 5 November 2026 market close. Companies without complete current figures were left out.
Click Here – Get Free Investment Predictions
What Are Hotel, Explosives and Oncology Pharma Stocks?
Hotel, explosives and oncology pharma stocks are listed companies that own and manage hotels across Indian cities, make industrial explosives and defence products, and develop and sell specialty medicines including cancer therapies. Their earnings depend on room demand, mining and defence orders and drug sales.
Hotel, Explosives and Oncology Pharma Stocks at a Glance
| Company | CMP (Rs) | Market Cap (Rs Cr) | P/E | Industry P/E | ROE (%) | D/E |
|---|---|---|---|---|---|---|
| SAMHI Hotels | 164.13 | 3,256 | 5.7 | 37.9 | 18.4 | 0.85 |
| Solar Industries India | 18,520 | 178,992 | 87.3 | 48.1 | 26.7 | 0.24 |
| Natco Pharma | 796.6 | 15,708 | 13.7 | 36.0 | 15.4 | 0.08 |
On valuation, SAMHI Hotels and Natco Pharma trade at a P/E below the industry P/E, while Solar Industries India trades above it, which reflects the growth the market already expects. Readers comparing hotel, explosives and oncology pharma stocks should look at return on equity and debt together, since a high return earned with low debt is easier to sustain.
Why Do Hotel, Explosives and Oncology Pharma Stocks Have a Strong Roadmap in India?
Hotel, explosives and oncology pharma stocks have a strong roadmap in India because growing business and leisure travel, rising mining and defence output and steady demand for specialty medicines keep widening the market for these companies.
- Hotels. Business and leisure trips fill city rooms.
- Explosives. Mining and defence need dependable products.
- Specialty pharma. Patients need advanced therapies.
Why SAMHI Hotels Features Among These Hotel, Explosives and Oncology Pharma Stocks
Among the hotel, explosives and oncology pharma stocks on this list, SAMHI Hotels owns and operates a portfolio of branded hotels across Indian cities, working with leading global hotel chains and focusing on business and leisure travellers.
In the June 2026 quarter, revenue grew 7.3% year on year to Rs 308 crore, while net profit rose 29.7% to Rs 24.9 crore. Revenue rose from Rs 333 crore in FY22 to Rs 1,279 crore in FY26, a compound annual growth rate of 40.0%.
Net profit for FY26 was Rs 503 crore, a net margin of 39.3%. The company has a return on equity of 18.4%, a debt to equity ratio of 0.85 and a market capitalisation of Rs 3,256 crore. The stock trades at a P/E of 5.7, below the industry P/E of 37.9.
Roadmap: The company is adding rooms through new hotels and expansions, helped by strong demand from business travel and domestic tourism. A focus on well-located properties supports occupancy.
What to watch: Track room additions, occupancy and average room rates.
Why Solar Industries India Features Among These Hotel, Explosives and Oncology Pharma Stocks
Among the stay, mining blast and cancer drug shares on this list, Solar Industries India is the country’s largest maker of commercial explosives and also produces defence products such as ammunition, rockets, propellants and warheads for domestic and export customers.
The company has a return on equity of 26.7%, a debt to equity ratio of 0.24 and a market capitalisation of Rs 178,992 crore. The stock trades at a P/E of 87.3, above the industry P/E of 48.1.
Revenue rose from Rs 3,967 crore in FY22 to Rs 9,966 crore in FY26, a compound annual growth rate of 25.9%. Net profit grew from Rs 455 crore in FY22 to Rs 1,737 crore in FY26, which works out to a compound annual growth rate of 39.7%.
Roadmap: The company serves mining and infrastructure customers with bulk and packaged explosives and has grown its defence business with large export orders. Capacity additions in defence manufacturing and a global presence widen its reach.
What to watch: Monitor the defence order book and the pace of new capacity in ammunition and rocket systems.
Why Natco Pharma Features Among These Hotel, Explosives and Oncology Pharma Stocks
Among the three companies on this list, Natco Pharma is a Hyderabad-based pharmaceutical company focused on complex generics, oncology, and active ingredients, with a significant presence in the United States and other regulated markets.
Revenue rose from Rs 2,044 crore in FY22 to Rs 4,376 crore in FY26, a compound annual growth rate of 21.0%. Net profit grew from Rs 170 crore in FY22 to Rs 1,372 crore in FY26, which works out to a compound annual growth rate of 68.5%.
The company has a return on equity of 15.4%, a debt to equity ratio of 0.08 and a market capitalisation of Rs 15,708 crore. The stock trades at a P/E of 13.7, below the industry P/E of 36.0.
Roadmap: The company has a track record of developing difficult-to-make generics and has built a strong position in oncology and specialty drugs. New product launches in regulated markets and investments in research support the pipeline.
What to watch: Check the timing of key product launches in the US and the contribution from new drug approvals.
SAMHI Hotels vs Solar Industries India vs Natco Pharma on Key Financials
The table below sets the three hotel, explosives and oncology pharma stocks side by side on revenue, profit and margin, using reported figures.
| Company | FY22 Revenue (Rs Cr) | FY26 Revenue (Rs Cr) | Revenue CAGR (FY22-FY26) | FY26 Net Profit (Rs Cr) | FY26 Net Margin |
|---|---|---|---|---|---|
| SAMHI Hotels | 333 | 1,279 | 40.0% | 503 | 39.3% |
| Solar Industries India | 3,967 | 9,966 | 25.9% | 1,737 | 17.4% |
| Natco Pharma | 2,044 | 4,376 | 21.0% | 1,372 | 31.4% |
Solar Industries India posts the highest return on equity in this group at 26.7%. Solar Industries India has the largest FY26 revenue at Rs 9,966 crore, and SAMHI Hotels shows the fastest revenue growth with a 40.0% compound annual rate. A useful habit with hotel, explosives and oncology pharma stocks is to check each new quarterly result against the capacity plans the company described earlier.
Key Risks to Check Before Investing in Hotel, Explosives and Oncology Pharma Stocks
Every theme carries risks that deserve a check before any decision. For these hotel, explosives and oncology pharma stocks, the main points are: Long-term stay, mining blast and cancer drug shares holders usually track revenue growth, margins and cash flow side by side rather than relying on a single ratio.
- Travel cycles. Bookings and occupancy follow travel demand.
- Order timing. Defence and space orders can shift between periods.
- Valuation levels. Some of these companies trade at high earnings multiples, so growth must continue to justify them.
Treat this list as a starting point for research and not as a recommendation. Read the latest results presentation, check the management commentary on order books or capacity plans, and compare each company with its peers before you decide anything.
Use the Univest Stock Screener to filter hotel, explosives and oncology pharma stocks by market capitalisation, P/E, ROE and growth, and build your own shortlist.
Final Thoughts on Hotel, Explosives and Oncology Pharma Stocks
Hotel, explosives and oncology pharma stocks work best when investors track growth, valuation and return on equity side by side. SAMHI Hotels, Solar Industries India and Natco Pharma each have a clear plan to grow. Based on the 5 November 2026 close, SAMHI Hotels trades at Rs 164.13, Solar Industries India at Rs 18,520 and Natco Pharma at Rs 796.6.
Download the Univest iOS App or Univest Android App to track hotel, explosives and oncology pharma stocks, set price alerts and get research-backed stock ideas.
Disclaimer: Data and figures in this article are sourced from publicly available information. These may or may not be accurate. Please verify all data with the official NSE (nseindia.com) and BSE (bseindia.com) websites before making any investment decision. Investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice by Univest (SEBI RA INH000013776).
What are hotel, explosives and oncology pharma stocks?
Ans. Hotel, explosives and oncology pharma stocks are listed companies that own and manage hotels across Indian cities, make industrial explosives and defence products, and develop and sell specialty medicines including cancer therapies. Their earnings depend on room demand, mining and defence orders and drug sales. This list looks at three of them, SAMHI Hotels, Solar Industries India and Natco Pharma, using reported FY22 to FY26 financials and the 5 November 2026 closing prices.
Which hotel, explosives and oncology pharma stocks are covered in this list?
Ans. This list covers SAMHI Hotels, Solar Industries India and Natco Pharma. Based on the 5 November 2026 close, SAMHI Hotels traded at Rs 164.13, Solar Industries India at Rs 18,520 and Natco Pharma at Rs 796.6. Their return on equity ranges from 15.4% to 26.7%, and their revenue compound annual growth from FY22 to FY26 ranges from 21.0% to 40.0%.
Why do hotel, explosives and oncology pharma stocks have a strong future roadmap in India?
Ans. Hotel, explosives and oncology pharma stocks have a strong roadmap in India because growing business and leisure travel, rising mining and defence output and steady demand for specialty medicines keep widening the market for these companies. The main drivers are as follows. Hotels. Business and leisure trips fill city rooms. Explosives. Mining and defence need dependable products. Specialty pharma. Patients need advanced therapies. Together these factors give the companies on this list a visible path for growth over the coming years.
How has SAMHI Hotels performed financially?
Ans. Revenue rose from Rs 333 crore in FY22 to Rs 1,279 crore in FY26, a compound annual growth rate of 40.0%. Net profit for FY26 was Rs 503 crore, a net margin of 39.3%. In the June 2026 quarter, revenue grew 7.3% year on year to Rs 308 crore, while net profit rose 29.7% to Rs 24.9 crore. The company has a return on equity of 18.4%, a debt to equity ratio of 0.85 and a market capitalisation of Rs 3,256 crore. The stock trades at a P/E of 5.7, below the industry P/E of 37.9. Looking ahead, the company is adding rooms through new hotels and expansions, helped by strong demand from business travel and domestic tourism. A focus on well-located properties supports occupancy.
How has Solar Industries India performed financially?
Ans. Revenue rose from Rs 3,967 crore in FY22 to Rs 9,966 crore in FY26, a compound annual growth rate of 25.9%. Net profit grew from Rs 455 crore in FY22 to Rs 1,737 crore in FY26, which works out to a compound annual growth rate of 39.7%. The company has a return on equity of 26.7%, a debt to equity ratio of 0.24 and a market capitalisation of Rs 178,992 crore. The stock trades at a P/E of 87.3, above the industry P/E of 48.1. Looking ahead, the company serves mining and infrastructure customers with bulk and packaged explosives and has grown its defence business with large export orders. Capacity additions in defence manufacturing and a global presence widen its reach.
How has Natco Pharma performed financially?
Ans. Revenue rose from Rs 2,044 crore in FY22 to Rs 4,376 crore in FY26, a compound annual growth rate of 21.0%. Net profit grew from Rs 170 crore in FY22 to Rs 1,372 crore in FY26, which works out to a compound annual growth rate of 68.5%. The company has a return on equity of 15.4%, a debt to equity ratio of 0.08 and a market capitalisation of Rs 15,708 crore. The stock trades at a P/E of 13.7, below the industry P/E of 36.0. Looking ahead, the company has a track record of developing difficult-to-make generics and has built a strong position in oncology and specialty drugs. New product launches in regulated markets and investments in research support the pipeline.
What risks should investors check before buying hotel, explosives and oncology pharma stocks?
Ans. Investors should check a few risks before buying hotel, explosives and oncology pharma stocks. Travel cycles. Bookings and occupancy follow travel demand. Order timing. Defence and space orders can shift between periods. Valuation levels. Some of these companies trade at high earnings multiples, so growth must continue to justify them. Reading the latest results presentation and comparing each company with its peers helps judge how these risks apply to each stock.
Is this list of hotel, explosives and oncology pharma stocks investment advice?
Ans. No. This article is educational and uses publicly available data as of the 5 November 2026 close. Please verify figures on NSE and BSE, read company filings and consult a SEBI registered adviser before investing. Univest is SEBI registered research analyst INH000013776.
